Needle-Delivered cancer treatment shows promise in early trials

NCT ID NCT07339176

Summary

This study is testing an experimental medicine called N17350, which is injected directly into tumors of adults with advanced solid cancers that have spread or stopped responding to standard treatments. The main goals are to find the safest and most effective dose, check for side effects, and see if the injections cause tumors to shrink or stop growing. All participants will receive N17350 injections into their tumors every two weeks for 8-12 weeks while being closely monitored.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Westmead Hospital

    Westmead, New South Wales, 2145, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.